BioMarin Pharmaceutical Inc. (BMRN) Expected to Announce Quarterly Sales of $410.84 Million

Brokerages forecast that BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will report $410.84 million in sales for the current fiscal quarter, according to Zacks Investment Research. Eleven analysts have issued estimates for BioMarin Pharmaceutical’s earnings, with the highest sales estimate coming in at $421.90 million and the lowest estimate coming in at $399.30 million. BioMarin Pharmaceutical reported sales of $372.85 million in the same quarter last year, which would suggest a positive year over year growth rate of 10.2%. The company is scheduled to report its next earnings results on Thursday, August 1st.

According to Zacks, analysts expect that BioMarin Pharmaceutical will report full-year sales of $1.69 billion for the current year, with estimates ranging from $1.67 billion to $1.71 billion. For the next year, analysts expect that the company will post sales of $1.95 billion, with estimates ranging from $1.81 billion to $2.11 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that follow BioMarin Pharmaceutical.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Thursday, April 25th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.02. The firm had revenue of $400.70 million during the quarter, compared to analyst estimates of $389.95 million. BioMarin Pharmaceutical had a negative net margin of 5.90% and a negative return on equity of 2.97%. The business’s revenue was up 7.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.12 earnings per share.

Several analysts recently weighed in on BMRN shares. ValuEngine downgraded BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a report on Wednesday, February 20th. Robert W. Baird set a $120.00 price objective on BioMarin Pharmaceutical and gave the company a “buy” rating in a report on Tuesday, April 2nd. Oppenheimer decreased their price objective on BioMarin Pharmaceutical from $92.00 to $81.00 in a report on Friday, February 22nd. BidaskClub upgraded BioMarin Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Thursday, February 28th. Finally, Barclays restated a “hold” rating and issued a $95.00 price objective on shares of BioMarin Pharmaceutical in a report on Sunday, February 24th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $116.00.

In other BioMarin Pharmaceutical news, insider Henry J. Fuchs sold 2,196 shares of the business’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $95.00, for a total value of $208,620.00. Following the completion of the transaction, the insider now directly owns 142,504 shares in the company, valued at $13,537,880. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jean Jacques Bienaime sold 4,000 shares of the business’s stock in a transaction dated Wednesday, May 8th. The stock was sold at an average price of $82.16, for a total transaction of $328,640.00. Following the completion of the transaction, the chief executive officer now owns 326,520 shares of the company’s stock, valued at $26,826,883.20. The disclosure for this sale can be found here. Insiders sold 103,011 shares of company stock valued at $9,215,368 over the last quarter. 1.90% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in BMRN. Doyle Wealth Management acquired a new position in shares of BioMarin Pharmaceutical during the fourth quarter valued at about $26,000. Rational Advisors LLC increased its holdings in shares of BioMarin Pharmaceutical by 3,211.1% during the first quarter. Rational Advisors LLC now owns 298 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 289 shares in the last quarter. Commonwealth Bank of Australia increased its holdings in shares of BioMarin Pharmaceutical by 49.6% during the fourth quarter. Commonwealth Bank of Australia now owns 350 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 116 shares in the last quarter. Lindbrook Capital LLC acquired a new position in shares of BioMarin Pharmaceutical during the fourth quarter valued at about $30,000. Finally, PRW Wealth Management LLC acquired a new position in shares of BioMarin Pharmaceutical during the fourth quarter valued at about $30,000. Institutional investors and hedge funds own 99.55% of the company’s stock.

BMRN stock opened at $87.16 on Thursday. The company has a quick ratio of 2.76, a current ratio of 3.83 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $14.73 billion, a P/E ratio of -264.12 and a beta of 1.46. BioMarin Pharmaceutical has a 1-year low of $79.13 and a 1-year high of $106.74.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Further Reading: Candlestick

Get a free copy of the Zacks research report on BioMarin Pharmaceutical (BMRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply